These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 20584125)

  • 1. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
    Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
    J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
    Mueller A; Kiesewetter F; Binder H; Beckmann MW; Dittrich R
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3470-5. PubMed ID: 17579193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of three different testosterone formulations in female-to-male transsexual persons.
    Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC
    J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
    Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G
    J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females.
    Gooren LJG; Giltay EJ
    J Sex Med; 2008 Apr; 5(4):765-776. PubMed ID: 17971101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.
    Mueller A; Zollver H; Kronawitter D; Oppelt PG; Claassen T; Hoffmann I; Beckmann MW; Dittrich R
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):95-100. PubMed ID: 20625973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    J Sex Med; 2007 Sep; 4(5):1479-84. PubMed ID: 17635694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.
    Young NR; Baker HW; Liu G; Seeman E
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1028-32. PubMed ID: 8408450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    Eur J Endocrinol; 2009 Nov; 161(5):795-8. PubMed ID: 19749027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
    Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy.
    Traish AM; Gooren LJ
    J Sex Med; 2010 Nov; 7(11):3758-64. PubMed ID: 20722789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of androgen treatment on bone metabolism in female-to-male transsexuals.
    Lips P; van Kesteren PJ; Asscheman H; Gooren LJ
    J Bone Miner Res; 1996 Nov; 11(11):1769-73. PubMed ID: 8915785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study.
    Vita R; Settineri S; Liotta M; Benvenga S; Trimarchi F
    Maturitas; 2018 Jan; 107():92-96. PubMed ID: 29169588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sex pattern of bone mineral density in early onset gender identity disorder.
    Haraldsen IR; Haug E; Falch J; Egeland T; Opjordsmoen S
    Horm Behav; 2007 Sep; 52(3):334-43. PubMed ID: 17604029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
    Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
    Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.